Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071339 | 1.00 | CYP2A6 (0.54) | CYP2A6CYP1A2IDO1ADRA2AG6PD | |
| SCHEMBL4107750 | 0.83 | CYP1A2 (0.54) | CYP2A6CYP1A2IDO1G6PDJAK2 | |
| SCHEMBL1458869 | 0.77 | CYP2A6 (0.52) | CYP2A6CYP1A2IDO1HPRT1 | |
| SCHEMBL30366567 | 0.77 | CYP2A6 (0.58) | CYP2A6CYP1A2ADRA2ANR4A2 | |
| SCHEMBL6561452 | 0.77 | CYP2A6 (0.58) | CYP2A6CYP1A2ADRA2ANR4A2 | |
| SCHEMBL5668937 | 0.76 | CYP2A6 (0.62) | CYP2A6CYP1A2ADRA2ANR4A2 | |
| SCHEMBL29972350 | 0.76 | CYP2A6 (0.62) | CYP2A6CYP1A2ADRA2ANR4A2 | |
| SCHEMBL30377849 | 0.75 | CYP1A2 (0.52) | CYP2A6CYP1A2IDO1HPRT1 | |
| SCHEMBL9040617 | 0.75 | ALDH1A1 (0.64) | CYP2A6CYP1A2HPRT1 | |
| SCHEMBL3275947 | 0.74 | CYP1A2 (0.63) | CYP2A6CYP1A2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | OSAKA UNIVERSITY (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | OSAKA UNIVERSITY (JP) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | CYP24A1, CYP26B1, CYP21A2 | CYP2A6 96/4885CYP1A2 115/4885IDO1 1496/4885 |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | CYP24A1, CYP26B1, CYP21A2 | CYP2A6 96/4885CYP1A2 115/4885IDO1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.